Advertisement
U.S. markets closed
  • S&P 500

    5,123.41
    -75.65 (-1.46%)
     
  • Dow 30

    37,983.24
    -475.84 (-1.24%)
     
  • Nasdaq

    16,175.09
    -267.10 (-1.62%)
     
  • Russell 2000

    2,003.17
    -39.43 (-1.93%)
     
  • Crude Oil

    85.45
    +0.43 (+0.51%)
     
  • Gold

    2,360.20
    -12.50 (-0.53%)
     
  • Silver

    27.97
    -0.28 (-0.99%)
     
  • EUR/USD

    1.0646
    -0.0085 (-0.79%)
     
  • 10-Yr Bond

    4.4990
    -0.0770 (-1.68%)
     
  • GBP/USD

    1.2451
    -0.0104 (-0.83%)
     
  • USD/JPY

    153.2400
    +0.0370 (+0.02%)
     
  • Bitcoin USD

    63,721.22
    -3,192.41 (-4.77%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • Nikkei 225

    39,523.55
    +80.92 (+0.21%)
     

CVS Health Beats 2Q Estimates, Top Analyst Sticks To Hold

CVS Health reported better-than-expected 2Q earnings and raised its full-year guidance. The company is bullish on its diverse business, including its drugstore chain and health benefits, and believes that it is well-positioned to weather the impact of the coronavirus pandemic.

CVS Health (CVS) reported 2Q adjusted earnings of $2.64 per share, up from $1.89 per share in the year-ago period, and beating analysts’ estimates of $1.93 per share. Revenue during the reported quarter grew 3% to $65.3 billion year-on-year marginally higher than the Wall Street consensus of $64.2 billion.

For the full-year, the company raised its adjusted earnings guidance to $7.14- $7.27, from the earlier forecast of $7.04 -$7.17. CVS now expects full-year cash flow from operations to be between $11 billion-$11.5 billion, up from the previous guidance of $10.5 billion-$11 billion.

Oppenheimer analyst Michael Wiederhorn maintained a Hold rating on the stock saying: “The Retail segment softened after a robust end to Q1 ($1.06B vs OPCO/Street $1.15B/$1.34B) due to COVID-related impacts to op-expenses and volumes, while the Pharmacy segment ($1.33B vs. OPCO/Street $1.28B/$1.34B) was largely in-line, overcoming softer new prescriptions and incremental costs.”

Currently, the Street has a cautiously optimistic outlook on the stock. The Moderate Buy analyst consensus is based on 5 Buys and 4 Holds. The average price target of $74.71 implies an upside potential of about 15%. (See CVS stock analysis on TipRanks).

Related News:
Zimmer Biomet Slips 3.7% On 2Q Profit Decline
Fiverr Pops 18% In Pre-Market On Upbeat 2Q Earnings And Raised Outlook
Square’s 64% Revenue Spike Pushes Shares Up 9% In Pre-Market

More recent articles from Smarter Analyst:

Advertisement